GSK-3/CDK5/CDK2-IN-1

• CAT Number: I044560
• CAS Number: 395074-72-3
• Molecular Formula: C21H22N4O2
• Molecular Weight: 362.42
• Purity: ≥95%
• Synonyms: N-[1-(3-acetamidocyclobutyl)imidazol-4-yl]-2-naphthalen-2-ylacetamide
• InChI: InChI=1S/C21H22N4O2/c1-14(26)23-18-10-19(11-18)25-12-20(22-13-25)24-21(27)9-15-6-7-16-4-2-3-5-17(16)8-15/h2-8,12-13,18-19H,9-11H2,1H3,(H,23,26)(H,24,27)
• InChIKey: XJRCZTVFSOVAQW-UHFFFAOYSA-N
• SMILES: CC(=O)NC1CC(C1)N2C=C(N=C2)NC(=O)CC3=CC4=CC=CC=C4C=C3

GSK-3/CDK5/CDK2-IN-1（Cat No.:I044560）is a multi-targeted small-molecule inhibitor designed to simultaneously inhibit glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase 5 (CDK5), and cyclin-dependent kinase 2 (CDK2). These kinases play pivotal roles in cell cycle regulation, neuronal signaling, and neurodegenerative disease progression. By targeting all three, the inhibitor exerts broad modulatory effects on tau phosphorylation, neuroinflammation, and abnormal cell proliferation. It shows promise in preclinical models for treating Alzheimer’s disease, cancer, and other CNS disorders. GSK-3/CDK5/CDK2-IN-1 offers a valuable pharmacological tool for studying complex kinase signaling networks and developing multifunctional therapeutic strategies.